查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631199

骨髓增生性疾病藥物市場規模、佔有率、趨勢分析報告：按適應症、治療類型、最終用途、地區和細分市場進行預測，2025 年至 2030 年

Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication (Ph+ Chronic Myelogenous Leukemia (CML)), By Treatment Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

骨髓增生性疾病藥物市場的成長與趨勢

根據 Grand View Research, Inc. 的新報告，全球治療骨髓增生性疾病的藥物市場規模預計到 2030 年將達到 158.3 億美元，2025 年至 2030 年期間的複合年成長率為 5.9%。新藥的可用性、強大產品線的存在、由於生活方式的改變而導致的骨髓增生性疾病盛行率的上升、老年人口的增加以及社會意識的增強是市場成長的主要刺激因素。針對 Jakafi 不耐受患者的二線治療的開發預計將有利於 Ph-MPN 市場。

慢性骨髓增生性疾病 (CMD) 是一種罕見的血液系統惡性腫瘤，其特徵是成熟的髓細胞（紅血球、粒細胞和血小板）及其前驅細胞（中幼粒細胞、晚幼粒細胞、有核紅血球和巨核細胞）在周邊血液和/或骨髓中異常積聚。此疾病分類包括四種主要的骨髓增生性疾病，根據費城染色體的存在或不存在進一步分類。

北美和西歐的骨髓增生性疾病發生率高於東亞國家。大多數患者在 60 歲後才被診斷出患有 MPN，但該疾病可發生在任何年齡。由於目標人口龐大，美國是治療骨髓增生性疾病藥物的主要市場。

骨髓增生性疾病藥物市場報告重點

  • 預計北美骨髓增生性疾病藥物市場將在 2024 年佔據全球市場的主導地位，收入佔有率為 40.2%，這得益於骨髓增生性疾病的高盛行率和支持創新療法的先進醫療基礎設施。
  • 強勁的未滿足需求預計將塑造市場的未來，並推動突破性的First-in-Class治療方法的發展。在存在未滿足需求的 MPN 中，有對比 Jakafi 更安全、治癒率更高、過敏反應更少的藥物的未滿足需求。
  • 主要市場參與企業包括諾華、百時美施貴寶、輝瑞、工業、Insight 和 Teva。主要企業的關鍵策略包括進入市場聯盟和在新興市場的地域擴張。

目錄

第1章調查方法與範圍

第 2 章執行摘要

3. 骨髓增生性疾病藥物市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析 – 波特五力分析
    • PESTLE分析

第4章：骨髓增生性疾病藥物市場：適應症業務分析

  • 2024 年和 2030 年指示市場佔有率
  • 指示細分儀表板
  • 2018 年至 2030 年按適應症分類的市場規模、預測與趨勢分析
  • Ph+慢性骨髓性白血病(CML)
  • Ph- 骨髓增生性腫瘤 (MPN)

5. 骨髓增生性疾病治療市場：治療類型業務分析

  • 2024 年和 2030 年治療類型市場佔有率
  • 治療類型細分儀表板
  • 2018 年至 2030 年按治療類型分類的市場規模、預測和趨勢分析
  • 化療
  • 標靶治療
  • 其他

6. 骨髓增生性疾病治療市場-最終用途業務分析

  • 2024 年及 2030 年終端用途市場佔有率
  • 最終用途細分儀表板
  • 2018 年至 2030 年按最終用途分類的市場規模、預測和趨勢分析
  • 醫院
  • 專科門診
  • 其他

第 7 章 骨髓增生性疾病藥物市場：按地區分類的估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030 年市場規模及預測趨勢分析
  • 北美洲
    • 按國家/地區，2018 年至 2030 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區，2018 年至 2030 年
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區，2018 年至 2030 年
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 按國家/地區，2018 年至 2030 年
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited.
    • Incyte.
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie Inc.
    • Eli Lilly and Company.
    • GSK plc.
    • GL Pharma
Product Code: GVR-2-68038-436-9

Myeloproliferative Disorders Drugs Market Growth & Trends:

The global myeloproliferative disorders drugs market size is expected to reach USD 15.83 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Availability of novel drugs, the presence of a strong pipeline, rising incidence of myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market. Therapeutic development in the second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph- MPNs market.

Chronic myeloproliferative disorders are rare hematological malignances that involve the abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.

There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group. The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to the presence of a large target population.

Myeloproliferative Disorders Drugs Market Report Highlights:

  • North America myeloproliferative disorders drugs market dominated the global market with a revenue share of 40.2% in 2024, driven by high prevalence rates of myeloproliferative disorders coupled with advanced healthcare infrastructure that supports innovative treatments.
  • Strong unmet needs are likely to shape the future of the market and encourage the development of breakthrough first-in-class therapies. Opportunities remain in the Ph- MPNs setting where there exists an unmet need for a safer drug than Jakafi with higher cure rates and lesser allergic effects
  • Some of the key market participants are Novartis, Bristol-Myers Squibb, Pfizer, Takeda, Incyte, and Teva. Primary go-to strategies of prominent players include collaborations for the development and regional expansion in emerging markets.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Treatment Type
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Myeloproliferative Disorders Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Myeloproliferative Disorders Drugs Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2030
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Billion)
  • 4.4. Ph+ Chronic Myelogenous Leukemia (CML)
    • 4.4.1. Ph+ Chronic Myelogenous Leukemia (CML) Market, 2018 - 2030 (USD Billion)
  • 4.5. Ph- Myeloproliferative Neoplasms (MPNs)
    • 4.5.1. Ph- Myeloproliferative Neoplasms (MPNs) Market, 2018 - 2030 (USD Billion)
    • 4.5.2. Myelofibrosis (MF)
    • 4.5.3. Myelofibrosis (MF) Market, 2018 - 2030 (USD Billion)
    • 4.5.4. Polycythemia Vera (PV)
    • 4.5.5. Polycythemia Vera (PV) Market, 2018 - 2030 (USD Billion)
    • 4.5.6. Essential Thrombocythemia (ET)
    • 4.5.7. Essential Thrombocythemia (ET) Market, 2018 - 2030 (USD Billion)

Chapter 5. Myeloproliferative Disorders Drugs Market: Treatment Type Business Analysis

  • 5.1. Treatment Type Market Share, 2024 & 2030
  • 5.2. Treatment Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2018 to 2030 (USD Billion)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy Market, 2018 - 2030 (USD Billion)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Myeloproliferative Disorders Drugs Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
  • 6.5. Specialty Clinics
    • 6.5.1. Specialty Clinics Market, 2018 - 2030 (USD Billion)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. Myeloproliferative Disorders Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. MEA
    • 7.8.1. MEA Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Novartis AG
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Bristol-Myers Squibb Company
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Pfizer Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Takeda Pharmaceutical Company Limited.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Incyte.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Teva Pharmaceutical Industries Ltd.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. AbbVie Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Eli Lilly and Company.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. GSK plc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. GL Pharma
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global myeloproliferative disorders drugs market, by region, 2018 - 2030 (USD Billion)
  • Table 4 Global myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 5 Global myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 6 Global myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 7 North America myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
  • Table 8 North America myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 9 North America myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 10 North America myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 11 U.S. myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 12 U.S. myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 13 U.S. myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 14 Canada myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 15 Canada myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 16 Canada myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 17 Mexico myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 18 Mexico myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 19 Mexico myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 20 Europe myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
  • Table 21 Europe myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 22 Europe myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 23 Europe myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 24 UK myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 25 UK myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 26 UK myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 27 Germany myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 28 Germany myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 29 Germany myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 30 France myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 31 France myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 32 France myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 33 Italy myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 34 Italy myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 35 Italy myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 36 Spain myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 37 Spain myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 38 Spain myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 39 Norway myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 40 Norway myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 41 Norway myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 42 Denmark myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 43 Denmark myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 44 Denmark myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 45 Sweden myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 46 Sweden myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 47 Sweden myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 48 Asia Pacific myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
  • Table 49 Asia Pacific myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 50 Asia Pacific myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 51 Asia Pacific myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 52 Japan myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 53 Japan myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 54 Japan myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 55 China myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 56 China myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 57 China myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 58 India myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 59 India myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 60 India myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 61 Australia myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 62 Australia myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 63 Australia myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 64 South Korea myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 65 South Korea myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 66 South Korea myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 67 Thailand myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 68 Thailand myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 69 Thailand myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 70 Latin America myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
  • Table 71 Latin America myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 72 Latin America myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion
  • Table 73 Latin America myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion
  • Table 74 Brazil myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 75 Brazil myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 76 Brazil myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 77 Argentina myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 78 Argentina myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 79 Argentina myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 80 Middle East & Africa myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
  • Table 81 Middle East & Africa myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 82 Middle East & Africa myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 83 Middle East & Africa myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 84 South Africa myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 85 South Africa myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 86 South Africa myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 87 Saudi Arabia myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 88 Saudi Arabia myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 89 Saudi Arabia myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 90 UAE myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 91 UAE myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 92 UAE myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
  • Table 93 Kuwait myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
  • Table 94 Kuwait myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
  • Table 95 Kuwait myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Myeloproliferative disorders drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Indication outlook (USD Billion)
  • Fig. 10 Treatment type outlook (USD Billion)
  • Fig. 11 End use outlook (USD Billion)
  • Fig. 12 Competitive landscape
  • Fig. 13 Myeloproliferative disorders drugs market dynamics
  • Fig. 14 Myeloproliferative disorders drugs market: Porter's five forces analysis
  • Fig. 15 Myeloproliferative disorders drugs market: PESTLE analysis
  • Fig. 16 Myeloproliferative disorders drugs market: Indication segment dashboard
  • Fig. 17 Myeloproliferative disorders drugs market: Indication market share analysis, 2024 & 2030
  • Fig. 18 Ph+ Chronic myelogenous leukemia (CML) market, 2018 - 2030 (USD Billion)
  • Fig. 19 Ph- Myeloproliferative neoplasms (MPNs) market, 2018 - 2030 (USD Billion)
  • Fig. 20 Myelofibrosis (MF) market, 2018 - 2030 (USD Billion)
  • Fig. 21 Polycythemia vera (PV) market, 2018 - 2030 (USD Billion)
  • Fig. 22 Essential thrombocythemia (ET) market, 2018 - 2030 (USD Billion)
  • Fig. 23 Myeloproliferative disorders drugs market: Treatment type segment dashboard
  • Fig. 24 Myeloproliferative disorders drugs market: Treatment type market share analysis, 2024 & 2030
  • Fig. 25 Chemotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 26 Targeted therapy market, 2018 - 2030 (USD Billion)
  • Fig. 27 Others market, 2018 - 2030 (USD Billion)
  • Fig. 28 Myeloproliferative disorders drugs market: End use segment dashboard
  • Fig. 29 Myeloproliferative disorders drugs market: End use market share analysis, 2024 & 2030
  • Fig. 30 Hospitals market, 2018 - 2030 (USD Billion)
  • Fig. 31 Specialty clinics market, 2018 - 2030 (USD Billion)
  • Fig. 32 Others market, 2018 - 2030 (USD Billion)
  • Fig. 33 Myeloproliferative disorders drugs market revenue, by region
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 36 U.S. country dynamics
  • Fig. 37 U.S. myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 38 Canada country dynamics
  • Fig. 39 Canada myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 40 Mexico country dynamics
  • Fig. 41 Mexico myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 42 Europe myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 43 UK country dynamics
  • Fig. 44 UK myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 45 Germany country dynamics
  • Fig. 46 Germany myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 47 France country dynamics
  • Fig. 48 France myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 49 Italy country dynamics
  • Fig. 50 Italy myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 51 Spain country dynamics
  • Fig. 52 Spain myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 53 Norway country dynamics
  • Fig. 54 Norway myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion
  • Fig. 57 Sweden country dynamics
  • Fig. 58 Sweden myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 59 Asia Pacific myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 60 Japan country dynamics
  • Fig. 61 Japan myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 62 China country dynamics
  • Fig. 63 China myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 64 India country dynamics
  • Fig. 65 India myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 68 Australia country dynamics
  • Fig. 69 Australia myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 70 Thailand country dynamics
  • Fig. 71 Thailand myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 72 Latin America myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 73 Brazil country dynamics
  • Fig. 74 Brazil myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 75 Argentina country dynamics
  • Fig. 76 Argentina myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 77 MEA myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 78 South Africa country dynamics
  • Fig. 79 South Africa myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 80 Saudi Arabia country dynamics
  • Fig. 81 Saudi Arabia myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 82 UAE country dynamics
  • Fig. 83 UAE myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 84 Kuwait country dynamics
  • Fig. 85 Kuwait myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
  • Fig. 86 Company categorization
  • Fig. 87 Company market position analysis
  • Fig. 88 Strategic framework